{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:30:56Z","timestamp":1762507856512,"version":"build-2065373602"},"reference-count":45,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcardioanesthesia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiothoracic and Vascular Anesthesia"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1053\/j.jvca.2019.08.046","type":"journal-article","created":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T19:19:00Z","timestamp":1567538340000},"page":"1925-1932","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Anesthesiologists Guide to the 2019 AHA\/ACC\/HRS Focused Update for the Management of Patients With Atrial Fibrillation"],"prefix":"10.1053","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6054-9650","authenticated-orcid":false,"given":"Adam A.","family":"Dalia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathew","family":"Vanneman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome","family":"Crowley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Elhassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.jvca.2019.08.046_bib0001","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"64","author":"January","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2019.08.046_bib0002","first-page":"104","volume":"74","author":"January","year":"2019","journal-title":"Heart Rhythm"},{"key":"10.1053\/j.jvca.2019.08.046_bib0003","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2019.08.046_bib0004","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2019.08.046_bib0005","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2019.08.046_bib0006","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2019.08.046_bib0007","doi-asserted-by":"crossref","first-page":"j3782","DOI":"10.1136\/bmj.j3782","article-title":"Indications for anticoagulant and antiplatelet combined therapy","volume":"359","author":"Floyd","year":"2017","journal-title":"BMJ"},{"key":"10.1053\/j.jvca.2019.08.046_bib0008","first-page":"888","article-title":"A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial","volume":"38","author":"Fanola","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2019.08.046_bib0009","doi-asserted-by":"crossref","first-page":"A17277","DOI":"10.1161\/circ.132.suppl_3.17277","article-title":"Apixaban use in patients with atrial fibrillation with bioprosthetic valves: Insights from ARISTOTLE [abstract 17277]","volume":"132","author":"Pokorney","year":"2015","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2019.08.046_bib0010","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1093\/eurheartj\/ehu046","article-title":"Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: Observations from the ARISTOTLE trial","volume":"35","author":"Halvorsen","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2019.08.046_bib0011","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors","volume":"380","author":"Connolly","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2019.08.046_bib0012","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrcardio.2017.223","article-title":"Reversal agents for non-vitamin K antagonist oral anticoagulants","volume":"15","author":"Levy","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"10.1053\/j.jvca.2019.08.046_bib0013","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s11239-018-1612-7","article-title":"Novel oral anticoagulants in the preoperative period: A meta-analysis","volume":"45","author":"He","year":"2018","journal-title":"J Thromb Thrombolysis"},{"key":"10.1053\/j.jvca.2019.08.046_bib0014","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1378\/chest.14-2710","article-title":"Timing the first postoperative dose of anticoagulants: Lessons learned from clinical trials","volume":"148","author":"Paikin","year":"2015","journal-title":"Chest"},{"key":"10.1053\/j.jvca.2019.08.046_bib0015","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/AAP.0000000000000763","article-title":"Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine evidence-based guidelines (fourth edition)","volume":"43","author":"Horlocker","year":"2018","journal-title":"Reg Anesth Pain Med"},{"key":"10.1053\/j.jvca.2019.08.046_bib0016","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/j.jacc.2017.03.600","article-title":"Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction","volume":"69","author":"Yao","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2019.08.046_bib0017","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1213\/ANE.0000000000002369","article-title":"Perioperative acute kidney injury: An under-recognized problem","volume":"125","author":"Meersch","year":"2017","journal-title":"Anesth Analg"},{"key":"10.1053\/j.jvca.2019.08.046_bib0018","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.amjcard.2017.09.030","article-title":"Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and end-stage renal disease","volume":"121","author":"Nishimura","year":"2018","journal-title":"Am J Cardiol"},{"key":"10.1053\/j.jvca.2019.08.046_bib0019","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1016\/j.jacc.2017.09.1087","article-title":"Renal outcomes in anticoagulated patients with atrial fibrillation","volume":"70","author":"Yao","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2019.08.046_bib0020","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004509","article-title":"National trends and impact of acute kidney injury requiring hemodialysis in hospitalizations with atrial fibrillation","volume":"5","author":"Chan","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1053\/j.jvca.2019.08.046_bib0021","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.ahj.2012.03.011","article-title":"A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN)","volume":"163","author":"Van de Werf","year":"2012","journal-title":"Am Heart J"},{"key":"10.1053\/j.jvca.2019.08.046_bib0022","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2019.08.046_bib0023","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1056\/NEJMoa1501035","article-title":"BRIDGE Investigators. Perioperative bridging anticoagulation in patients with atrial fibrillation","volume":"373","author":"Douketis","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2019.08.046_bib0024","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.04.006","article-title":"Perioperative heparin bridging in atrial fibrillation patients requiring temporary interruption of anticoagulation: Evidence from meta-analysis","volume":"25","author":"Ayoub","year":"2016","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1053\/j.jvca.2019.08.046_bib0025","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/0003-4975(95)00887-X","article-title":"Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation","volume":"61","author":"Blackshear","year":"1996","journal-title":"Ann Thorac Surg"},{"key":"10.1053\/j.jvca.2019.08.046_bib0026","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1161\/CIRCULATIONAHA.112.114389","volume":"127","author":"Reddy","year":"2013","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2019.08.046_bib0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2014.04.029","article-title":"Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: The PREVAIL trial","volume":"64","author":"Holmes","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2019.08.046_bib0028","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1016\/j.jacc.2017.10.021","article-title":"PREVAIL and PROTECT AF Investigators. 5-Year outcomes after left atrial appendage closure: From the PREVAIL and PROTECT AF trials","volume":"70","author":"Reddy","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2019.08.046_bib0029","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1053\/j.jvca.2019.01.054","article-title":"Left atrial appendage occlusion: A narrative review","volume":"33","author":"Alsagheir","year":"2019","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1053\/j.jvca.2019.08.046_bib0030","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1053\/j.jvca.2019.01.049","article-title":"The year in electrophysiology: Selected highlights from 2018","volume":"33","author":"Cronin","year":"2019","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1053\/j.jvca.2019.08.046_bib0031","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0735-1097(00)00765-8","article-title":"Surgical left atrial appendage ligation is frequently incomplete: A transesophageal echocardiograhic study","volume":"36","author":"Katz","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2019.08.046_bib0032","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1001\/jama.2018.6024","article-title":"Association of surgical left atrial appendage occlusion with subsequent stroke and mortality among patients undergoing cardiac surgery","volume":"319","author":"Yao","year":"2018","journal-title":"JAMA"},{"key":"10.1053\/j.jvca.2019.08.046_bib0033","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jacc.2013.04.089","article-title":"Thromboembolic complications after cardioversion of acute atrial fibrillation: The FinCV (Finnish CardioVersion) study","volume":"62","author":"Airaksinen","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2019.08.046_bib0034","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jacep.2016.01.018","article-title":"Incidence of thromboembolic complications within 30 days of electrical cardioversion performed within 48 hours of atrial fibrillation onset","volume":"2","author":"Garg","year":"2016","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1053\/j.jvca.2019.08.046_bib0035","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1001\/jama.2014.3824","article-title":"Time to cardioversion for acute atrial fibrillation and thromboembolic complications","volume":"312","author":"Nuotio","year":"2014","journal-title":"JAMA"},{"key":"10.1053\/j.jvca.2019.08.046_bib0036","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1080\/07853890.2016.1267869","article-title":"Sex, age, and time to cardioversion. Risk factors for cardioversion of acute atrial fibrillation from the FinCV study","volume":"49","author":"Bah","year":"2017","journal-title":"Ann Med"},{"key":"10.1053\/j.jvca.2019.08.046_bib0037","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1093\/eurheartj\/ehu367","article-title":"Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation","volume":"35","author":"Cappato","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2019.08.046_bib0038","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(16)31474-X","article-title":"Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): A randomised, open label, phase 3b trial","volume":"388","author":"Goette","year":"2016","journal-title":"Lancet"},{"key":"10.1053\/j.jvca.2019.08.046_bib0039","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1707855","article-title":"Catheter ablation for atrial fibrillation with heart failure","volume":"378","author":"Marrouche","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2019.08.046_bib0040","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ahj.2018.02.015","article-title":"Catheter ablation versus antiarrhythmic drug therapy for atrial fibrillation (CABANA) trial: Study rationale and design","volume":"199","author":"Packer","year":"2018","journal-title":"Am Heart J"},{"key":"10.1053\/j.jvca.2019.08.046_bib0041","first-page":"141","article-title":"Catheter ablation vs. antiarrhythmic drug therapy for atrial fibrillation: The results of the Cabana Multicenter International Randomized Clinical Trial [abstract B-LBCT01-05]","volume":"15","author":"Packer","year":"2018","journal-title":"Heart Rhythm"},{"key":"10.1053\/j.jvca.2019.08.046_bib0042","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"10.1053\/j.jvca.2019.08.046_bib0043","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jacc.2013.05.029","article-title":"Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention","volume":"62","author":"Lamberts","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2019.08.046_bib0044","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1001\/jama.2013.280521","article-title":"Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: A randomized clinical trial","volume":"310","author":"Abed","year":"2013","journal-title":"JAMA"},{"key":"10.1053\/j.jvca.2019.08.046_bib0045","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.jacc.2014.09.028","article-title":"Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study","volume":"64","author":"Pathak","year":"2014","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of Cardiothoracic and Vascular Anesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053077019309139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053077019309139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T07:49:30Z","timestamp":1760946570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053077019309139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S1053077019309139"],"URL":"https:\/\/doi.org\/10.1053\/j.jvca.2019.08.046","relation":{},"ISSN":["1053-0770"],"issn-type":[{"type":"print","value":"1053-0770"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anesthesiologists Guide to the 2019 AHA\/ACC\/HRS Focused Update for the Management of Patients With Atrial Fibrillation","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiothoracic and Vascular Anesthesia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.jvca.2019.08.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}